Troubled VaxGen Inc. traded up slightly on word that $11 million is coming from the feds after the anthrax vaccine was cancelled, but Thursday's conference call updating investors might have done little to quell concerns about the future. (BioWorld Today)

As consumer advocates trumpeted their victory, others took a longer view of the U.S. Patent and Trademark Office's preliminary denial of claims in three stem cell patents held by the Wisconsin Alumni Research Foundation (WARF). (BioWorld Today)

As much as $154.9 million in cash gained from the sale of its sequencing subsidiary, 454 Life Sciences, to Roche Diagnostics Corp. will help CuraGen Corp. get at least one cancer drug into Phase III trials by next year - not a bad return for the $36.1 million investment made when 454 was founded. (BioWorld Today)